Equitable Access to High-Cost Pharmaceuticals

Seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by-country analysis of policy and regulation, the work compares and contrasts national healthcare systems to support researchers and practitioners in identifying optimal healthcare policy solutions.

The work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement, and post-launch monitoring are considered in detail.

The work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

Evaluates impact and efficacy of current access policies and pricing regulation of high-cost drugs

Incorporates existing guidelines and recommendations by international organizations

Compares and contrasts how different countries fund and police high-cost drug access

Explores novel and emergent policies, including managed entry agreement, analysis of real world data, and differential pricing

Reviews novel pharmaceuticals of current research interest